GSK Calls For Preemption Ruling In Zofran Birth Defect MDL

By Mike Curley · July 19, 2019, 4:08 PM EDT

GlaxoSmithKline has renewed its bid to end multidistrict litigation in Massachusetts federal court over claims it didn't warn customers about alleged birth defects resulting from its anti-nausea medication, saying a recent...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation

Case Number

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

October 13, 2015

Recent Articles By Mike

November 19, 2024
Widow Can't Get Malpractice Suit Over Husband's Fall Revived
November 13, 2024
TikTok Asks To Keep NC AG's Addiction Complaint Redacted
November 07, 2024
Albany, NY, Nursing Home Hit With $2M Verdict Over Death
November 06, 2024
Mom Files $25M Med Mal Suit Against Feds Over Son's Death
November 04, 2024
Hospital Can't Undo Widow's $5M Win Over Husband's Suicide
October 11, 2024
Texan Who Sued Ex's Colleagues Over Abortion Drops Suit
October 09, 2024
Patients' Families Say No Expert Needed In Transplant Case
October 09, 2024
Philips Preserves Lanham Act Counterclaim In CPAP Cleaner MDL
October 09, 2024
Companies' Kratom Supplements Are Addictive, Class Says
September 26, 2024
Winner Of $8.6M Suit Wants Mich. Justices' Take On Cap